NASDAQ: NRXPNrx Pharmaceuticals Inc Stock
$4.46+0.28 (+6.7%)
Updated Jul 21, 2026
NRXP Price
$4.46
Fair Value Price
$0.58
Market Cap
$161.58M
52 Week Low
$1.62
52 Week High
$5.06
P/E
-4.09x
P/B
-11.7x
P/S
30.03x
PEG
N/A
Dividend Yield
N/A
Revenue
$2.29M
Earnings
-$24.54M
Gross Margin
50.5%
Operating Margin
-1,030.83%
Profit Margin
-1,070.3%
Debt to Equity
-1.86
Operating Cash Flow
-$15M
Beta
1.11
Next Earnings
Aug 17, 2026
Ex-Dividend
N/A
Next Dividend
N/A
NRXP Overview
NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm focused on developing innovative therapies for disorders of the central nervous system and critical lung diseases. Its product portfolio features ZYESAMI, an experimental medication that has successfully completed Phase IIb/III clinical trials for treating respiratory failure associated with COVID-19. Additionally, the company is advancing NRX-100 and NRX-101, a pair of oral therapeutics designed to address bipolar depression, specifically in patients exhibiting acute or sub-acute suicidal thoughts and behaviors. Established in 2015, NRx Pharmaceuticals is headquartered in Wilmington, Delaware.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine NRXP's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +5.11% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
NRXP
Ranked#205 of 464
Ranked#205 of 464
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $254.22 | A | |
| $11.20 | A | |
| $8.78 | A |
Be the first to know about important NRXP news, forecast changes, insider trades & much more!
NRXP News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how NRXP scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
NRXP ($4.46) is overvalued by 671.06% relative to our estimate of its Fair Value price of $0.58 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
NRXP ($4.46) is not significantly undervalued (671.06%) relative to our estimate of its Fair Value price of $0.58 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
NRXP is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more NRXP due diligence checks available for Premium users.
Valuation
NRXP fair value
Fair Value of NRXP stock based on Discounted Cash Flow (DCF)
Price
$4.46
Fair Value
$0.58
Overvalued by
671.06%
NRXP ($4.46) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
NRXP ($4.46) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
NRXP is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
NRXP price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-4.09x
Industry
21.35x
Market
12.07x
NRXP price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-11.7x
Industry
5.42x
NRXP's financial health
Profit margin
Revenue
$1.1M
Net Income
-$1.4M
Profit Margin
-133.9%
NRXP's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
NRXP's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$11.9M
Liabilities
$25.7M
Debt to equity
-1.86
NRXP's short-term liabilities ($25.18M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
NRXP's short-term assets ($7.36M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
NRXP's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
NRXP's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$4.3M
Investing
-$213.0k
Financing
$3.4M
NRXP's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
NRXP vs Biotech Stocks
Nrx Pharmaceuticals Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.